Back to Interventions
Substance / Medication

Cefditoren

SNOMED 708598002UMLS C0287573

Overview

Active Ingredient
cefditoren
RxNorm CUI
83682

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Bronchitis
Haemophilus infection
Bacterial pneumonia
Streptococcal infectious disease
Bacterial infectious disease
Soft tissue infection
Staphylococcal infection of skin
Pharyngitis
Infection caused by Klebsiella

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

14 trials linked to this intervention

14
Total Trials
1
Recruiting
1
With Results

Recent Trials

Recurrent Throat Infections and Tonsillectomy

NCT00547391Phase 4Completed87 enrolled

Post Operative Sore Throat and Dexamethasone

NCT01052038Phase 4Completed120 enrolled

Efficacy of Tinoridine in Treating Pain and Inflammation in Adults

NCT01224756Phase 4Completed342 enrolled

Clinical Trial for the Assessment of Delayed Antibiotic Treatment Strategies

NCT01363531Phase 4Completed405 enrolled

Impact of Four Patient Information Leaflets (PIL) on Patient Behaviour

NCT01398696Phase 4Completed400 enrolled
View all 14 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
A prospective, randomized, double dummy, placebo-controlled trial of oral cefditoren pivoxil 400mg once daily as switch therapy after intravenous ceftriaxone in the treatment of acute pyelonephritis.
Monmaturapoj Teerapong, Montakantikul Preecha, Mootsikapun Piroon et al. · Int J Infect Dis · 2012
PMID: 22951426RCT
Exploring therapeutic options for mild diabetic-related foot infections: a comparative in vitro study of cefditoren versus amoxicillin/clavulanic acid.
Alou L, Gómez-Rubio E, Giménez Mestre M J et al. · Rev Esp Quimioter · 2024
PMID: 38864830ObservationalFull text (PMC)
Efficacy and safety of cefditoren pivoxil for exacerbations of chronic obstructive pulmonary disease: A prospective multicenter interventional study.
Miyazaki Taiga, Fukushima Kiyoyasu, Hashiguchi Kohji et al. · J Infect Chemother · 2019
PMID: 30982729Observational
Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: multicentre, randomized, open-label trial.
Sadahira Takuya, Wada Koichiro, Araki Motoo et al. · J Antimicrob Chemother · 2017
PMID: 27733519Observational
In vitro antibacterial activities of two novel oral antibiotics, tebipenem and cefditoren, and other comparators against community-acquired respiratory tract infection-associated bacterial pathogens: a multicentre study in China.
Li Henan, Wang Zhanwei, Zhang Feifei et al. · Int J Antimicrob Agents · 2014
PMID: 24183753Observational
Cefditoren: Comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients.
Hatzaki Despina, Poulakou Garyphallia, Katsarolis Ioannis et al. · BMC Infect Dis · 2012
PMID: 23009290ObservationalFull text (PMC)
Efficacy of simulated cefditoren versus amoxicillin-clavulanate free concentrations in countering intrastrain ftsI gene diffusion in Haemophilus influenzae.
González Natalia, Aguilar Lorenzo, Sevillano David et al. · Antimicrob Agents Chemother · 2011
PMID: 21464255ObservationalFull text (PMC)
[Antibiotic therapy against acute tonsillopharyngitis in children due to group A beta-hemolytic streptococci: comparison of clinical efficacy, the bactericidal effects, and effects on oral flora between cefditoren pivoxil for 5 days and amoxicillin for 10 days].
Tsumura Naoki, Nagai Kensuke, Hidaka Hidenobu et al. · Jpn J Antibiot · 2011
PMID: 21861309Observational
Cefditoren versus ceftazidime in inducer-substrate combinations for the evaluation of AmpC production in a disc approximation test.
Cafini F, Aguilar L, Alou L et al. · Rev Esp Quimioter · 2010
PMID: 20559604Observational
Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study.
Cuevas Oscar, Cercenado Emilia, Gimeno Mercedes et al. · Diagn Microbiol Infect Dis · 2010
PMID: 20542206Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cefditoren (substance)
SNOMED CT
708598002
UMLS CUI
C0287573
RxNorm CUI
83682

Clinical Data

This intervention maps to 9 entities in the Healos knowledge graph.

9
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
14
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.